Trial reportThe oncologist2016
Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.
Trial report in The oncologist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 91 citations in OpenAlex.
- Financial reimbursement for clinical trial participation costs: a pilot feasibility study.JNCI cancer spectrum · 2026Trial
- Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial.JCO oncology practice · 2022Trial
- Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial.Integrative cancer therapies · 2018Trial
- Feasibility and Acceptability of Automated Texts to Offer, Screen, and Enroll Patients in a Cancer Clinical Trial Financial Reimbursement Program: Mixed Methods Study.JMIR formative research · 2026Article
- Associations of symptom burden with patient-reported outcomes and clinical outcomes among early phase cancer clinical trial participants.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Eligibility criteria and study phase limit racial/ethnic enrollment in oncology clinical trials.BMC cancer · 2026Article
- Assessing patient risk, benefit, and outcomes in drug development: a decade of sorafenib clinical trials.European journal of clinical pharmacology · 2026Review
- Underrepresentation of Racial and Ethnic Minorities in Metastatic Colorectal Carcinoma Clinical Trials Within the United States.Annals of surgery · 2026Article
- Enrollment Patterns and Site-Level Predictors of Black Participant Recruitment to a Multisite Randomized Cancer Clinical Trial.JCO oncology advances · 2025Article
- Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000-2023): A Cohort Study.Cancer discovery · 2025Article
- Clinical trial-related financial considerations from Deep South-patients with breast cancer who previously declined trial participation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Beyond Barriers: Achieving True Equity in Cancer Care.Current oncology (Toronto, Ont.) · 2025Review
- Interventions to Address Cancer-Related Financial Hardship: A Scoping Review and Call to Action.JCO oncology practice · 2025Article
- The intersection of travel burdens and financial hardship in cancer care: a scoping review.JNCI cancer spectrum · 2024Article
- Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials.Cancer medicine · 2024Article
- Addressing transportation barriers in oncology: existing programs and new solutions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Understanding the financial cost of cancer clinical trial participation.Cancer medicine · 2024Article
- The Inclusion of Underrepresented Populations in Cardiovascular Genetics and Epidemiology.Journal of cardiovascular development and disease · 2024Review
- Breast Cancer-Related Financial Toxicity in Sri Lanka: Insights From a Lower Middle-Income Country With Free Universal Public Healthcare.The oncologist · 2024Article
- Enhancing Catchment Area Tools: A De-Identification Method for Integrating Clinical Trial Data with Cancer InFocus.Preventive oncology & epidemiology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCancer clinical trial (CT) participation rates are low and financial barriers likely play a role. We implemented a cancer care equity program (CCEP) to address financial burden associated with trial participation. We sought to examine the impact of the CCEP on CT enrollment and to assess barriers to participation.
methodsWe used an interrupted time series design to determine trends in CT enrollment before and after CCEP implementation. Linear regression models compared trial enrollment before and after the CCEP. We also compared patient characteristics before and after the CCEP and between CCEP and non-CCEP participants. We surveyed CCEP and non-CCEP participants to compare pre-enrollment financial barriers.
resultsAfter accounting for increased trial availability and the trends in accrual for prior years, we found that enrollment increased after CCEP implementation (18.97 participants per month greater than expected; p < .001). A greater proportion of CCEP participants were younger, female, in phase I trials, lived farther away, had lower incomes, and had metastatic disease. Of 87 participants who completed the financial barriers survey, 49 CCEP and 38 matched, non-CCEP participants responded (63% response rate). CCEP participants were more likely to report concerns regarding finances (56% vs. 11%), medical costs (47% vs. 14%), travel (69% vs. 11%), lodging (60% vs. 9%), and insurance coverage (43% vs. 14%) related to trial participation (all p < .01).
conclusionCT participation increased following implementation of the CCEP and the program enrolled patients experiencing greater financial burden. These findings highlight the need to address the financial burden associated with CT participation. IMPLICATIONS FOR PRACTICE: Financial barriers likely discourage patients from participating in clinical trials. Implementation of a cancer care equity program (CCEP) seeking to reduce financial barriers by assisting with travel and lodging costs was associated with increased trial accrual. The CCEP provided assistance to patients particularly in need, including those living farther away, those with lower incomes, and those reporting financial barriers related to trial participation. These findings suggest that financial concerns represent a major barrier to patient participation in clinical trials and underscore the importance of efforts to address these concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.